


**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

Claim 1 (canceled)

Claim 2 (currently amended): A method of treating a warm-blooded animal having a hyperparathyroidism disease comprising treating the warm-blooded animal by administering a therapeutically effective amount of an epothilone derivative of formula I



wherein A represents O or NR<sub>N</sub>, wherein R<sub>N</sub> is hydrogen or lower alkyl, R is hydrogen or lower alkyl, R' is methyl, methoxy, ethoxy, amino, methylamino, dimethylamino or methylthio, and Z is O or a bond,  
or a pharmaceutically acceptable salt thereof ~~to a warm-blooded animal in need thereof.~~

Claim 3 (original): The method according to claim 2 wherein the warm-blooded animal is a human.

Claim 4 (currently amended): The method according to claim 2 ~~in which method~~ wherein an epothilone derivative of formula I wherein A represents O, R is methyl and Z is O or a pharmaceutically acceptable salt thereof is administered to a warm-blooded animal in need thereof.

Claim 5 (cancelled):


Claim 6 (previously presented): The method according to claim 2 wherein the hyperparathyroidism disease is adenoma, hyperplasia or carcinoma.

Claim 7 (original): The method according to claim 6 wherein the disease is parathyroid adenoma, parathyroid hyperplasia or parathyroid carcinoma.

Claim 8 (currently amended): The method according to claim 7 ~~2~~ wherein the ~~parathyroid cancer~~ disease is recurrent or persistent parathyroid adenoma, recurrent or persistent parathyroid hyperplasia or recurrent or persistent parathyroid carcinoma.

Claim 9 (previously presented): The method according to claim 2 wherein the hyperparathyroidism disease is primary or secondary hyperparathyroidism.

Claim 10 (currently amended): A method for the treatment of hypercalcemia resulting from a disease selected from parathyroid adenoma, parathyroid hyperplasia or parathyroid carcinoma comprising treating the disease by administering a therapeutically effective amount of an epothilone derivative of formula I



wherein A represents O or NRN, wherein RN is hydrogen or lower alkyl, R is hydrogen or lower alkyl, R' is methyl, methoxy, ethoxy, amino, methylamino, dimethylamino or methylthio, and Z is O ~~or a bond~~,

or a pharmaceutically acceptable salt thereof to a warm-blooded animal in need thereof.


Claim 11 (original): The method according to claim 10 wherein the warm-blooded animal is a human.

Claim 12 (currently amended): The method according to claim 10 ~~in which method~~ wherein an epothilone derivative of formula I wherein A represents O, R is methyl and Z is O or a pharmaceutically acceptable salt thereof is administered to a warm-blooded animal in need thereof.

Claim 13 (cancelled)


Claim 14 (previously presented): The method according to claim 10 wherein the disease is recurrent or persistent parathyroid adenoma, recurrent or persistent parathyroid hyperplasia or recurrent or persistent parathyroid carcinoma.

Claim 15 (original): A pharmaceutical composition comprising a quantity of compound of formula I



wherein A represents O or NRN, wherein RN is hydrogen or lower alkyl, R is hydrogen or lower alkyl, R' is methyl, methoxy, ethoxy, amino, methylamino, dimethylamino or methylthio, and Z is O or a bond, or a pharmaceutically acceptable salt thereof, which is therapeutically effective against hyperparathyroidism.

Claim 16 (original): A commercial package comprising a compound of formula I



wherein A represents O or NRN, wherein RN is hydrogen or lower alkyl, R is hydrogen or lower alkyl, R' is methyl, methoxy, ethoxy, amino, methylamino, dimethylamino or methylthio, and Z is O or a bond, or a pharmaceutically acceptable salt thereof, together with instructions for use thereof in the treatment of hyperparathyroidism.